2157. Phase 1 Study in Healthy Chinese Subjects of Novel Prodrug, MRX-4

BACKGROUND: MRX-4 is a prodrug of contezolid (MRX-1), a new oxazilidone approved in China. We evaluated the safety and pharmacokinetic (PK) profile of IV and oral MRX-4 and its metabolites. METHODS: This randomized, double-blind, placebo-controlled study was conducted at Huashan Hospital, (Shanghai,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Haijing, Li, Size, Wang, Hailin, Cao, Guoying, Zhang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677217/
http://dx.doi.org/10.1093/ofid/ofad500.1780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677217/
http://dx.doi.org/10.1093/ofid/ofad500.1780

Ejemplares similares